Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-02-08

Clinical Trial Update: Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) [Phase 4]

View source ↗

Summary

Phase 4 follow-up study of fingolimod in relapsing-remitting multiple sclerosis; results from the original biobank study were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2019-02-08